Robert Azelby - 01 Feb 2026 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role: Director
Signature: /s/ David Strauss, as Attorney-in-Fact for Robert Azelby
Issuer symbol: TERN
Transactions as of: 01 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2026, 18:06:50 UTC
Previous filing: 06 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Azelby Robert	Director	C/O TERNS PHARMACEUTICALS, INC., 1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY	/s/ David Strauss, as Attorney-in-Fact for Robert Azelby	02 Feb 2026	0001656998

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TERN	Stock Option (Right to Buy)	Award	$0	+1,697		$0.000000	1,697	01 Feb 2026	Common Stock	1,697	$34.60	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $45,000 for 2026.
F2	The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2026, such that 100% of the shares subject to the option will be fully vested on January 1, 2027.